Chemotherapeutic Mechanism of Action of the Synthetic Resorcinolic Methyl 3,5-dimethoxy-2-octanoylbenzoate

Willian Ayala Correa,Silvia Cordeiro das Neves,Rodrigo Juliano Oliveira,Cândida A. Kassuya,Stephanie D. Navarro,Allana Cristina Faustino Martins,Baby Saroja,Barbara Mitsuyasu,Ingridhy Ostaciana Maia Freitas da Silveira,Neimar Vitor,Henrique Rodrigues Scherer Coelho,Marcelo L. B. Vilela,Valter A. do Nascimento,Dênis P. de Lima,Adilson Beatriz,Roberto da Silva Gomes,Cândida A. Kassuya,Dênis P. de Lima
DOI: https://doi.org/10.1021/acs.chemrestox.3c00269
2024-01-06
Chemical Research in Toxicology
Abstract:Resorcinolic lipids are described as potential examples of selective chemotherapeutic adjuvants that can enhance the effects of cyclophosphamide (<b>CYC</b>) while promoting cell death without causing DNA damage. Therefore, the current study attempted to describe how the resorcinolic lipid methyl 3,5-dimethoxy-2-octanoylbenzoate (<b>AMS35BB</b>) interacted with DNA (DNA docking) and how this compound affected genetic toxicology models and other biological characteristics when combined with <b>CYC</b>. We observed that <b>AMS35BB</b>, used alone (7.5 and 10 mg/kg), increases the frequency of genomic damage (comet assay) but not chromosomal damage (micronuclei assay), lowers phagocytosis, and promotes cell death in Swiss male mice. When used in association with <b>CYC</b>, <b>AMS35BB</b> can reduce the risk of genomic damage by up to 33.8% as well as chromosomal damage, splenic phagocytosis, cell death, and lymphocyte frequency. Molecular docking showed that <b>AMS35BB</b> had a higher affinity than the active metabolite of <b>CYC</b> for binding to the DNA double helix major groove. As a result, <b>AMS35BB</b> has the potential to be both an adjuvant when used in association with <b>CYC</b> and a therapeutic candidate for the development of a selective chemotherapeutic drug.
chemistry, medicinal,toxicology, multidisciplinary
What problem does this paper attempt to address?